Your browser version may not work well with NCBI's Web applications. More information here...
1: Curr Opin Investig Drugs. 2001 May;2(5):650-3.Links

CLX-0901 (Calyx Therapeutics).

Barlocco D.

1st Chim Farmaceutico/Tossicologico, University of Milan, Italy. daniela.barlocco@unimi.it

Calyx Therapeutics is developing the insulin sensitizer, CLX-0901, as an antidiabetic agent. CLX-0901 is the synthetic analog of CLX-0900 which was originally isolated from a plant source. Phase I and toxicological studies indicate that the compound is safe and well tolerated [363764]. As of March 2001, phase II studies had commenced [402737]. Other antidiabetics being investigated by Calyx include CLX-0301, CLX-0921, CLX-0940, CLX-0100 and CLX-0101 [376032].

PMID: 11569941 [PubMed - indexed for MEDLINE]

Recent Activity